Physician

Carlos Eduardo Arce-Lara, M.D.

According to 2025 Medicare claims, Carlos Arce-Lara, M.D. (NPI: 1326265273) practices hematology/oncology in the Phoenix-Mesa-Chandler, AZ market, with the plurality of this provider's patient population coming from Pinal, AZ. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 85122-9998. Arce-Lara is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Arce-Lara's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 907 traditional Medicare patients, billed 264,781 HCPCS/CPT codes, and received $5,370,802 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,607 prescription claims across 398 beneficiaries totaling $7,120,126 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 51 claims. Open Payments data shows 39 records totaling $16,013. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $18,244 to $5,370,802. Similarly, Part D prescription costs have risen steadily, from $306,574 to $7,120,126. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	65	283	$18,244
2016	50	327	$32,780
2017	52	268	$29,396
2018	316	71,159	$1,050,287
2019	515	151,676	$3,042,701
2020	669	143,954	$2,698,368
2021	690	141,410	$2,591,778
2022	752	171,012	$3,435,510
2023	801	219,523	$3,977,845
2024	907	264,781	$5,370,802

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	40	341	$306,574
2016	45	299	$337,522
2017	36	281	$229,582
2018	123	444	$686,973
2019	228	1,340	$2,429,378
2020	316	1,352	$3,009,250
2021	262	1,012	$3,300,933
2022	185	467	$1,919,547
2023	270	890	$2,928,633
2024	398	1,607	$7,120,126

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	51	$5,630
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	209	209	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	610	1,332	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	285	422	$65
36415	Insertion of needle into vein for collection of blood sample	738	2,527	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	742	2,595	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	102	2,520	$1,525,594
Xtandi	Enzalutamide	41	1,230	$445,187
Calquence	Acalabrutinib Maleate	32	960	$444,650
Bosulif	Bosutinib	23	690	$442,990
Kisqali	Ribociclib Succinate	29	812	$442,568

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$1,660	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	16	$14,353	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Carlos Eduardo Arce-Lara, M.D.?

Tedicare shows public-source Medicare data for Carlos Eduardo Arce-Lara, M.D. (NPI 1326265273), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Carlos Eduardo Arce-Lara, M.D. have ACO affiliation data?

Carlos Eduardo Arce-Lara, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Carlos Eduardo Arce-Lara, M.D.?

Carlos Eduardo Arce-Lara, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Carlos Eduardo Arce-Lara, M.D. have Open Payments data?

Carlos Eduardo Arce-Lara, M.D. has 39 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.